Name: Exelixis Change in Accounts Receivable 2010-2025 | EXEL
Creator: MACROTRENDS
License: https://creativecommons.org/licenses/by/4.0/

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Exelixis annual change in accounts receivable for 2024 was $-0.028B, a 23.55% increase from 2023.
Exelixis annual change in accounts receivable for 2023 was $-0.023B, a 133.84% decline from 2022.
Exelixis annual change in accounts receivable for 2022 was $0.067B, a 154.65% decline from 2021.

Exelixis Change in Accounts Receivable 2010-2025 | EXEL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Exelixis annual change in accounts receivable for 2024 was $-0.028B, a 23.55% increase from 2023.
Exelixis annual change in accounts receivable for 2023 was $-0.023B, a 133.84% decline from 2022.
Exelixis annual change in accounts receivable for 2022 was $0.067B, a 154.65% decline from 2021.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$209.6B
Amgen (AMGN)	$149.1B
Gilead Sciences (GILD)	$130.2B
Vertex Pharmaceuticals (VRTX)	$125.6B
Bristol Myers Squibb (BMY)	$100.2B
CSL (CSLLY)	$74.3B
GSK (GSK)	$74.1B
Regeneron Pharmaceuticals (REGN)	$61.6B
Argenex SE (ARGX)	$36.2B
Alnylam Pharmaceuticals (ALNY)	$30.5B
BioNTech SE (BNTX)	$23.7B
BeiGene (ONC)	$22.8B
Biogen (BIIB)	$17.4B
Genmab (GMAB)	$13.3B
Genmab (GNMSF)	$13.3B
Insmed (INSM)	$13.2B
BioMarin Pharmaceutical (BMRN)	$11.3B
Illumina (ILMN)	$11.3B
Incyte (INCY)	$11.3B
Ascendis Pharma (ASND)	$10.1B
Swedish Orphan Biovitrum (BIOVF)	$9.6B
Moderna (MRNA)	$9.6B
QIAGEN (QGEN)	$9B
Exact Sciences (EXAS)	$7.7B
Bio-Techne Corp (TECH)	$7.6B
Repligen (RGEN)	$7.3B
Halozyme Therapeutics (HALO)	$7.3B
Roivant Sciences (ROIV)	$7.2B
Revolution Medicines (RVMD)	$6.8B
Bio-Rad Laboratories (BIO.B)	$6.3B